Remus Pharmaceuticals Limited (NSE:REMUS)

Remus Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	118.2	72.3	47.2	30.38	11.49
Short-Term Investments	430.9	200.4	202.4	-	-
Cash & Short-Term Investments	549.1	272.7	249.6	30.38	11.49
Cash Growth	101.36%	9.25%	721.54%	164.51%	38.30%
Accounts Receivable	1,398	1,080	1,153	48.48	29.15
Receivables	1,495	1,290	1,335	48.48	29.15
Inventory	720.6	515.6	431.1	2.87	15.89
Prepaid Expenses	4.6	3.2	0.4	0.49	0.07
Other Current Assets	177.2	131.9	107.7	31.22	20.34
Total Current Assets	2,946	2,214	2,123	113.44	76.94
Property, Plant & Equipment	178	70.2	48.6	25.13	3.09
Long-Term Investments	2,570	1,953	1,064	206.16	30.68
Goodwill	87.3	87.3	87.3	-	-
Other Intangible Assets	2.4	0.7	2.1	0.5	-
Long-Term Deferred Tax Assets	-	-	-	1.27	0.41
Other Long-Term Assets	2.1	1.2	5.9	0.12	47.49
Total Assets	5,787	4,326	3,331	346.61	158.6

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	760.4	712.9	937.1	35.31	46.73
Accrued Expenses	20.4	14.5	10.4	8.61	2.75
Short-Term Debt	170.4	171.2	83.4	6.38	-
Current Portion of Long-Term Debt	3.3	3.6	2.1	2.16	0.93
Current Portion of Leases	10.1	5.1	5.1	-	-
Current Income Taxes Payable	66.1	28.1	14.4	6.75	4.71
Other Current Liabilities	460.3	279.9	358.6	22.41	36.71
Total Current Liabilities	1,491	1,215	1,411	81.62	91.84
Long-Term Debt	56.7	33.3	30	70.89	0.99
Long-Term Leases	30.2	16.6	21.7	-	-
Pension & Post-Retirement Benefits	4.8	5.7	4.2	2.75	-
Long-Term Deferred Tax Liabilities	325.1	229	111.6	-	-
Other Long-Term Liabilities	1.4	1	0.4	-	-
Total Liabilities	1,909	1,501	1,579	155.26	92.82

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	117.8	58.9	14.7	10.85	10
Additional Paid-In Capital	504.3	504.3	504.7	41.65	-
Retained Earnings	871.1	571.9	337.1	138.86	55.78
Comprehensive Income & Other	2,017	1,424	720.4	-	-
Total Common Equity	3,510	2,559	1,577	191.36	65.78
Minority Interest	367.4	266.9	175.2	-	-
Shareholders' Equity	3,877	2,826	1,752	191.36	65.78
Total Liabilities & Equity	5,787	4,326	3,331	346.61	158.6

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	270.7	229.8	142.3	79.43	1.92
Net Cash (Debt)	278.4	42.9	107.3	-49.05	9.57
Net Cash Growth	548.95%	-60.02%	-	-	73.48%
Net Cash Per Share	23.63	7.28	9.50	-6.00	1.20
Filing Date Shares Outstanding	11.78	11.66	11.78	8.68	8.68
Total Common Shares Outstanding	11.78	11.66	11.78	8.68	8.68
Working Capital	1,455	998.4	712.2	31.82	-14.9
Book Value Per Share	297.85	219.47	133.82	22.05	7.58
Tangible Book Value	3,420	2,471	1,488	190.85	65.78
Tangible Book Value Per Share	290.24	211.92	126.23	21.99	7.58
Buildings	3.3	3.3	3.3	3.28	-
Machinery	99.6	71.4	35.8	31.07	7.89
Construction In Progress	82.8	-	0.1	0.22	-

Data Source: S&P Global Market Intelligence Last updated: Sep 8, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 3, 2026

Data Sources Report a data error